



August 8, 2016

## **Celsion Corporation to Hold Second Quarter 2016 Financial Results Conference Call on Monday, August 15, 2016**

LAWRENCEVILLE, N.J., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter and six-month period ended June 30, 2016 and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system at 11:00 a.m. EDT on Monday, August 15, 2016. To participate in the call, interested parties may dial 1-877-723-9521 (Toll-Free/North America) or 1-719-325-4925 (International/Toll) and ask for the Celsion Corporation 2nd Quarter 2016 Earnings Call (Conference Code: 3335946) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live over the internet at [www.celsion.com](http://www.celsion.com).

The call will be archived for replay on Monday, August 15, 2016 and will remain available until Monday, August 29, 2016. The replay can be accessed at 1-888-203-1112 (Toll-Free/North America) or 1-719-457-0820 (International/Toll) using Conference Code: 3335946. An audio replay of the call will also be available on the Company's website, [www.celsion.com](http://www.celsion.com), for 30 days after 2:00 p.m. EDT on Monday, August 15, 2016.

### **About Celsion Corporation**

Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in Phase II development for the treatment of recurrent chest wall breast cancer. The pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies, including TheraPlas™ and TheraSilence™. For more information on Celsion, visit our website: [www.celsion.com](http://www.celsion.com) (CLSN-FIN).

Celsion Investor Contact

Jeffrey W. Church

Sr. Vice President and CFO

609-482-2455

[jchurch@celsion.com](mailto:jchurch@celsion.com)

Source: Celsion Corporation

News Provided by Acquire Media